康臣药业(01681)今日盘中股价大涨逾5%,截至发稿时报8.09港元/股,成交量较昨日明显放大。公司最新业绩表现出色,加上机构力挺成为主要推手。
根据最新财报,康臣药业去年实现营收13.9亿港元、净利4.38亿港元,每股收益0.55港元,毛利率达74.7%。业绩表现优异令该股基本面备受认可。此外,分析人士认为,公司旗下多款主力产品线如肾科药物、妇儿药物行业地位稳固,未来发展前景广阔。
就在今日早盘,有2家券商给予康臣药业"买入"评级,并上调目标价至10港元以上,认为公司具备长期增长潜力。目前行业整体表现亦较为向好,药品生产和医疗健康板块领涨蓝筹,行业赶超效应也为康臣药业股价带来一定助力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.